Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.

CONCLUSION: Palbociclib has no significant clinical activity as a single agent in P16/CDKN2A deleted GIST refractory to Imatinib and Sunitinib.
PMID: 30979737 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 11, 2019 Category: Cancer & Oncology Authors: Toulmonde M, Bellera CA, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Le Loarer F, Italiano A Tags: Clin Cancer Res Source Type: research